Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK584449PMID: 36153937
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1340593-59-0
Drug Levels and Effects
Summary of Use during Lactation
Oteseconazole must not be used by women of reproductive potential because of the possibility of fetal or infant harm. It is extremely long-lasting and could remain in the milk for as long as 2 years after a course of therapy. An alternate drug should be used.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Oteseconazole
CAS Registry Number
1340593-59-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis.[J Biol Chem. 2017]Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis.Hargrove TY, Friggeri L, Wawrzak Z, Qi A, Hoekstra WJ, Schotzinger RJ, York JD, Guengerich FP, Lepesheva GI. J Biol Chem. 2017 Apr 21; 292(16):6728-6743. Epub 2017 Mar 3.
- Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.[Antimicrob Agents Chemother. 2...]Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.Hoekstra WJ, Hargrove TY, Wawrzak Z, da Gama Jaen Batista D, da Silva CF, Nefertiti AS, Rachakonda G, Schotzinger RJ, Villalta F, Soeiro Mde N, et al. Antimicrob Agents Chemother. 2016 Feb; 60(2):1058-66. Epub 2015 Dec 7.
- Review Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review.[Ann Pharmacother. 2024]Review Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review.Lanier C, Melton TC. Ann Pharmacother. 2024 Jun; 58(6):636-644. Epub 2023 Aug 31.
- "Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".[Heliyon. 2023]"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".Siddiqui T, Kumar KA, Iqbal A, Doultani PR, Ashraf T, Eqbal F, Siddiqui SI. Heliyon. 2023 Nov; 9(11):e20495. Epub 2023 Oct 20.
- Review Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).[Expert Rev Anti Infect Ther. 2...]Review Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).Vandecruys P, Baldewijns S, Sillen M, Van Genechten W, Van Dijck P. Expert Rev Anti Infect Ther. 2023 Jul-Dec; 21(8):799-812. Epub 2023 Jul 24.
- Oteseconazole - Drugs and Lactation Database (LactMed®)Oteseconazole - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...